ERBB2 and cancer: Previously, HER-2 overexpression has been shown in various cancer types (breast, ovarian and colorectal cancers) and it has been related to an increased probability of cancer recurrence and aggressive tumor growth as well as poor clinical outcomes [26,28,29].